Risk management in the treatment of type 2 diabetes with pioglitazone
Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. Insulin-resistance represents the common mechanism that leads to type 2 diabetes in...
Main Authors: | Giuseppe Derosa, Sibilla AT Salvadeo |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-07-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Online Access: | http://www.dovepress.com/risk-management-in-the-treatment-of-type-2-diabetes-with-pioglitazone-a3327 |
Similar Items
-
Optimizing combination treatment in the management of type 2 diabetes
by: Giuseppe Derosa, et al.
Published: (2007-11-01) -
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
by: Schwartz S
Published: (2010-07-01) -
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
by: Stanley S Schwartz
Published: (2010-07-01) -
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
by: Holl, et al.
Published: (2014-07-01) -
Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.
by: Belcher, G, et al.
Published: (2005)